Description

How This Works

AOD‑9604 is a modified C‑terminal fragment of human growth hormone that retains the lipolytic (fat‑reducing) domain without the growth‑promoting effects^[1]. It binds to adipose tissue and triggers breakdown of stored fat while blocking new fat storage (re‑esterification) in adipocytes^[4]. At the molecular level, chronic AOD‑9604 administration upregulates β₃‑adrenergic receptors in fat tissue, reversing obesity‑related suppression of these fat‑burning receptors^[9]. Unlike full‑length hGH, AOD‑9604 does not meaningfully elevate IGF‑1 levels or worsen glucose tolerance, making its tolerability indistinguishable from placebo in human trials^[2][3].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

• Supports reductions in fat mass and increases in fat oxidation over time; clinical trials showed modest but statistically significant weight loss (approximately 2.6 kg vs. 0.8 kg placebo over 12 weeks at 1 mg/day)^[10].
• Preferential loss of abdominal fat observed, resembling the pattern seen with low‑dose hGH therapy^[10].
• Does not meaningfully raise IGF‑1 and shows a placebo‑like safety profile in human studies; no anti‑AOD9604 antibodies detected^[2][3].
• Emerging regenerative potential: preclinical studies suggest possible cartilage repair and bone health benefits^[11][12].
• Generally well tolerated; occasional mild injection‑site reactions (redness/itch) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a hypocaloric, protein‑forward diet tailored to energy needs; AOD‑9604 is best viewed as a supportive aid to fat loss rather than a stand‑alone solution^[10].
• Combine resistance training and aerobic activity to reinforce metabolic adaptations.
• Prioritize sleep and stress management to support adherence and recovery.